Zymeworks Wins FDA Approval for Zanidatamab in Biliary Tract Cancer

Vancouver-based Zymeworks Inc. (NASDAQ: ZYME; TSX: ZYME) secured FDA approval on August 27, 2026, for zanidatamab (brand name: Ziihera) as a second-line treatment for HER2-amplified biliary tract cancer (BTC) — a rare but aggressive malignancy of the bile ducts and gallbladder. The approval covers adult patients whose disease has progressed on or after a gemcitabine-based regimen, making zanidatamab the first bispecific antibody approved in this indication in the United States.

What the Approval Covers

Zanidatamab is a bispecific antibody engineered to bind two distinct domains of the HER2 receptor simultaneously, delivering a more durable blockade than conventional HER2-targeted monoclonal antibodies. The approved indication is specifically limited to patients with HER2 amplification confirmed by an FDA-approved companion diagnostic — a requirement that narrows the eligible population to roughly 15–20% of all BTC cases. BTC as a whole affects approximately 12,000 new patients annually in the United States, implying an initial addressable pool of 1,800 to 2,400 patients per year in the U.S. alone.

The approval was supported by the HERIZON-BTC-01 pivotal trial, which demonstrated an objective response rate (ORR) of 41.3% and a median duration of response of 12.9 months in the HER2-amplified cohort — data the FDA’s Oncology Drugs Advisory Committee had previously described as “clinically meaningful in the context of an unmet need.” Median overall survival reached 15.5 months, comparing favourably against historical second-line benchmarks of 6–8 months in unselected BTC populations.

Commercial Opportunity and Competitive Landscape

Analysts at Canaccord Genuity estimate peak annual sales for zanidatamab in BTC of approximately USD $420 million (roughly CAD $582 million at today’s rate of 1.3862), with a potential label expansion into first-line BTC and gastroesophageal junction (GEJ) cancer capable of pushing the total franchise above USD $1.2 billion by 2031. The BTC second-line market has historically been dominated by off-label chemotherapy regimens; no HER2-targeted therapy held FDA approval in the indication prior to this decision. The closest competitive threat comes from AstraZeneca’s trastuzumab deruxtecan (Enhertu), which carries HER2 approvals in breast and gastric cancer but does not yet have a BTC-specific label — a gap zanidatamab now occupies exclusively.

Zymeworks retains full commercial rights in North America following its 2023 termination of the co-development agreement with Jazz Pharmaceuticals, a decision that initially weighed on the stock but now positions the company to capture the full U.S. margin. BeiGene holds commercialization rights in Asia, where BTC incidence rates are disproportionately high.

Stock Reaction and Long-Term Thesis

ZYME shares climbed 28.4% in pre-market trading on the Nasdaq following the FDA announcement, recovering ground lost during a six-week regulatory review extension in June 2026. On the TSX, the stock is expected to open near CAD $19.80, up from Wednesday’s close of CAD $15.42. The broader biotech environment offered a muted backdrop: the XBI ETF traded at $168.39 (-0.42%) and the IBB at $215.23 (-0.54%) as of Thursday’s open, meaning Zymeworks’ move was entirely company-specific rather than sector-driven.

For long-term investors, the critical next catalyst is the FDA’s review of zanidatamab’s BLA in HER2-overexpressing GEJ cancer, for which a PDUFA date is expected in Q1 2027. A second approval would more than double the addressable patient population in North America and materially de-risk Zymeworks’ path to cash-flow positivity — a milestone the company has guided for no earlier than fiscal 2028. Health Canada’s parallel review under the Priority Review designation remains ongoing; a Canadian approval decision is expected within 180 days of the U.S. action.